{"filing":{"accession_number":"0001104659-26-097091","cik":"0001477845","ticker":"ANVS","company_name":"Annovis Bio, Inc.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-14","primary_document":"tm2623272d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465926097091/tm2623272d1_8k.htm"},"events":[{"id":27879,"run_id":25455,"accession_number":"0001104659-26-097091","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02 Results of Operations and Financial Condition. The press release (Exhibit 99.1) discloses quarterly financial results including balance sheet, statement of operations, net loss per share ($0.40 basic and diluted), and key operational metrics. The filing explicitly states \"issued a press release reporting earnings for the quarter ended June 30, 2026.\"","company_name":"Annovis Bio, Inc.","ticker":"ANVS","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29586,"accession_number":"0001104659-26-097091","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02 Results of Operations and Financial Condition. The press release (Exhibit 99.1) discloses quarterly financial results including balance sheet, statement of operations, net loss per share ($0.40 basic and diluted), and key operational metrics. The filing explicitly states \"issued a press release reporting earnings for the quarter ended June 30, 2026.\"","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:17:52.075602+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29586,"accession_number":"0001104659-26-097091","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02 Results of Operations and Financial Condition. The press release (Exhibit 99.1) discloses quarterly financial results including balance sheet, statement of operations, net loss per share ($0.40 basic and diluted), and key operational metrics. The filing explicitly states \"issued a press release reporting earnings for the quarter ended June 30, 2026.\"","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:17:52.075602+00:00","company_name":"Annovis Bio, Inc.","ticker":"ANVS","filing_date":"2026-08-14"}]}